Visceral Fat’s Role in Disorders

Although in recent years numerous novel cancer therapies have been introduced, cisplatin along with its analogs (carboplatin, oxaliplatin, nedaplatin, lobaplatin, and satraplatin) remains central to the curative treatment for several major cancers, including testicular, ovarian, endometrial, lung, and head and neck malignancies, although toxicity precludes its prolonged administration in high doses.

One way to reduce toxicity while increasing efficacy is to use cisplatin at a lower, less toxic, dose together with another, even less toxic but also effective, drug.

The company developed such drug, CCL28, which was the most effective and least toxic among its structural analogs. In case of mouse models of human endometrial and ovarian tumors, CCL28 further enhanced the inhibitory effects of a nontoxic dose of cisplatin from 57% to 84% and 56% to 88%, respectively. Furthermore, adding CCLPr to the mix allowed doubling of the dose of cisplatin without increased toxicity and with further increase in the combined effects of cisplatin and CCL28. CCLPr greatly reduced the extent of cisplatin induced muscle loss in both tumor models which may contribute to its positive effects possibly among others.

Picture of a cancer patient with cachexia

CONCLUSION: Safe combined uses of cisplatin (or its analogs) and CCL28 to treat gynecological and other tumors in humans will likely require once a week addition of CCLPr to the treatment schedule to enhance efficacy and reduce muscle loss.